Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | EGLN1 | Q9GZT9 | 13/20 | 0.56 |
| ▸ | EGLN3 | Q9H6Z9 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.44 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.44 |
| ▸ | VEGFA | P15692 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2774138 | 0.88 | EGLN1 (0.48) | CYP2C19EGLN1EGLN3BBOX1VEGFA | |
| SCHEMBL2775364 | 0.86 | EGLN1 (0.53) | EGLN1EGLN3BBOX1FTOVEGFA | |
| SCHEMBL2774992 | 0.85 | SMN1; SMN2 (0.47) | CYP2C19EGLN1EGLN3BBOX1VEGFA | |
| SCHEMBL2775539 | 0.84 | EGLN1 (0.54) | EGLN1EGLN3FTOVEGFAFLT1 | |
| SCHEMBL2777174 | 0.83 | EGLN1 (0.56) | EGLN1EGLN3BBOX1VEGFAFLT1 | |
| SCHEMBL2776113 | 0.82 | EGLN1 (0.44) | CYP2C19EGLN1EGLN3 | |
| SCHEMBL2776647 | 0.82 | EGLN1 (0.60) | EGLN1EGLN3BBOX1VEGFAFLT1 | |
| SCHEMBL2777651 | 0.80 | EGLN1 (0.57) | EGLN1EGLN3BBOX1FTO | |
| SCHEMBL2775886 | 0.79 | EGLN1 (0.56) | EGLN1EGLN3VEGFAFLT1 | |
| SCHEMBL2774499 | 0.78 | MAPT (0.48) | CYP2C19MAPTPOLBTSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2227475-B1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | FIBROGEN INC (US) | 2014-02-19 | — | — | EP | claimed |
| US-8269008-B2 | Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions | FIBROGEN, INC. (US) | 2012-09-18 | — | — | US | claimed |
| US-20100303928-A1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | FIBROGEN, INC. (US) | 2010-12-02 | — | — | US | claimed |
| EP-2227475-B1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | FIBROGEN INC (US) | 2014-02-19 | — | — | EP | disclosed |
| US-8269008-B2 | Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions | FIBROGEN, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100303928-A1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | FIBROGEN, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| EP-2227475-A1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | Fibrogen, Inc. (US) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009073669-A1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | FIBROGEN, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100303928-A1 | ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS | HIF1AN, HIF1A, EGLN2 | CYP2C19 1557/4885EGLN1 5/4885EGLN3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.